Youjia Biopharmaceutical Technology

Youjia (Hangzhou) Biomedical Technology is an innovative Chinese biotechnology company specializing in the research and development of small nucleic acid (siRNA) therapeutics. Founded in 2019 and headquartered in Hangzhou, the company has established a comprehensive, end-to-end nucleic acid drug development platform. This platform includes its intelligent Novel Drug Delivery System (NDDS) for target selection and sequence design, CMS3 chemical modification technology, and diverse delivery systems such as GalNAc conjugates, lipid nanoparticles (LNP), and antibody-oligonucleotide conjugates (AOC). Youjia's pipeline covers major therapeutic areas including cardiovascular, metabolic, antiviral, and anti-fibrotic diseases. The company has established strategic partnerships with prominent pharmaceutical companies, including Livzon Pharmaceutical Group and Buchang Pharmaceuticals, to advance its innovative siRNA candidates into clinical development.